Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2026)

Xeris Biopharma Holdings' Operating Leases history runs 5 years deep, the most recent figure standing at $31.1 million for Q1 2026.

• Quarterly Operating Leases fell 5.51% year-over-year to $31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.1 million (down 5.51% YoY) and the FY2025 annual result came in at $31.5 million, down 5.2% from the prior year.
• Operating Leases was $31.1 million for Q1 2026 at Xeris Biopharma Holdings, down from $31.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $38.6 million in Q2 2025 and bottomed at $9.3 million in Q1 2023.
• A 5-year average of $30.8 million and a median of $33.8 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases surged 269.75% — and 2026, when it declined 5.51%.
• Xeris Biopharma Holdings' Operating Leases stood at $9.4 million in 2022, then jumped by 269.75% to $34.8 million in 2023, then retreated by 4.33% to $33.3 million in 2024, then declined by 5.2% to $31.5 million in 2025, then decreased by 1.5% to $31.1 million in 2026.
• Business Quant data shows XERS's Operating Leases at $31.1 million in Q1 2026, $31.5 million in Q4 2025, and $38.2 million in Q3 2025.